Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › ID › Twin Falls › NPI 1932381522

Southern Idaho Pain Institute P.C.

Southern Idaho Pain Institute P.C. was paid $800K by Medicaid between Jan 2018 and Feb 2023, across 7 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 44% of everything it billed.

33Billing provider infoSOUTHERN IDAHO PAIN INSTITUTE P.C.
TWIN FALLS, ID 83301
33aNPI1932381522assigned 12/05/2007
33bProvider typeSpecialist
28Total paid$800K
24GClaims15,966
24DCodes billed7
24AFirst – last monthJan 2018 – Feb 2023
Compared with peers

Next to other Specialist providers in Idaho

Rank by total paid#3 of 34
Median peer was paid$53K
This provider vs. median15×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$10K$20K$30K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20182,643$138K
20192,944$108K
20203,090$144K
20213,464$179K
20223,313$196K
2023512$35K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 44% 6,675 6,201 $352K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 21% 2,795 2,717 $167K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 13% 2,802 2,725 $103K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 11% 2,387 2,223 $88K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 10% 940 860 $81K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 339 305 $6K
62323 <1% 28 25 $3K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDILLE, CLINTON (M.D./ANESTHESIOLOGIST)